1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

17 May 2021
Admin
News Article

Torrent Pharma Enters Into Voluntary Licensing Agreement With Eli Lilly For Baricitinib For Covid-19

Torrent Pharmaceuticals Limited Announced That It Has Entered Into A Royalty Free, Non-Exclusive Voluntary Licensing Agreement With Eli Lilly And Company, Joining A Group Of Leading Indian Pharmaceutical Companies For Baricitinib For Covid-19 In India.Under The Agreement, Lilly Has Provided The License To Manufacture And Distribute Baricitinib To Torrent For India Along With Lilly&Rsquo;S Other License Partners.The Agreement Will Help Ensure Wider Reach And Access To Patients In India And Further Adds To Torrent Pharma&Rsquo;S Effort In Helping Patients Affected By The Pandemic. Baricitinib Has Been Approved By The Central Drug Standard Control Organisation (Cdsco), India For Restricted Emergency Use In Combination With Remdesivir For The Treatment Of Suspected Or Laboratory Confirmed Covid-19 In Hospitalized Adults Requiring Supplemental Oxygen, Invasive Mechanical Ventilation Or Extracorporeal Membrane Oxygenation.Commenting On The Agreement, Aman Mehta, Chief Marketing Officer For Torrent Said, &Ldquo;We Are Pleased To Partner And Work Closely With Lilly To Bring This Treatment To Market. This Partnership Further Strengthens Our Efforts To Help The Nation Fight The Pandemic And Provide Quality Treatment To Patients. Torrent Group Stands Firmly Committed To Support The Nation During This Time Of Crisis.&Rdquo;

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!